| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-107497 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M11-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B65D85-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2005-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2007-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2007538075-A |
| titleOfInvention |
Aerosolized fosfomycin / aminoglycoside combination for the treatment of bacterial respiratory infections |
| abstract |
A combination formulation of fosfomycin and tobramycin for delivery by aerosol administration is described. A concentrated fosfomycin and tobramycin combination formulation containing an effective amount of fosfomycin and tobramycin can inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated independently in a double ampoule so that the pH is about 4.5-8.0 when reconstituted, or formulated as a dry powder. Method for treating respiratory tract infections with a formulation delivered by an aerosol with a mean particle size of suspended particles mainly in the range of 1-5 μm produced by a jet or ultrasonic nebulizer (or equivalent) or a dry powder inhaler . |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015232026-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014523909-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013515079-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014526481-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10471083-B2 |
| priorityDate |
2004-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |